Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Current Liabilities (2020 - 2025)

RxSight's Total Current Liabilities history spans 6 years, with the latest figure at $26.3 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 1.46% year-over-year to $26.3 million; the TTM value through Dec 2025 reached $26.3 million, up 1.46%, while the annual FY2025 figure was $26.3 million, 1.46% up from the prior year.
  • Total Current Liabilities reached $26.3 million in Q4 2025 per RXST's latest filing, up from $22.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.3 million in Q4 2025 to a low of $9.2 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $17.8 million, with a median of $18.3 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: decreased 4.51% in 2021, then soared 78.38% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $11.1 million in 2021, then surged by 55.61% to $17.2 million in 2022, then increased by 21.27% to $20.9 million in 2023, then grew by 23.79% to $25.9 million in 2024, then increased by 1.46% to $26.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Total Current Liabilities are $26.3 million (Q4 2025), $22.3 million (Q3 2025), and $20.4 million (Q2 2025).